You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
|
|---|---|
| Published in |
BMC Nephrology, November 2017
|
| DOI | 10.1186/s12882-017-0688-1 |
| Pubmed ID | |
| Authors |
Ashraf Mikhail, Christopher Brown, Jennifer Ann Williams, Vinod Mathrani, Rajesh Shrivastava, Jonathan Evans, Hayleigh Isaac, Sunil Bhandari |
| Abstract |
Anaemia is a commonly diagnosed complication among patients suffering with chronic kidney disease. If left untreated, it may affect patient quality of life. There are several causes for anaemia in this patient population. As the kidney function deteriorates, together with medications and dietary restrictions, patients may develop iron deficiency, resulting in reduction of iron supply to the bone marrow (which is the body organ responsible for the production of different blood elements). Chronic kidney disease patients may not be able to utilise their own body's iron stores effectively and hence, many patients, particularly those receiving haemodialysis, may require additional iron treatment, usually provided by infusion.With further weakening of kidney function, patients with chronic kidney disease may need additional treatment with a substance called erythropoietin which drives the bone marrow to produce its own blood. This substance, which is naturally produced by the kidneys, becomes relatively deficient in patients with chronic kidney disease. Any patients will eventually require treatment with erythropoietin or similar products that are given by injection.Over the last few years, several iron and erythropoietin products have been licensed for treating anaemia in chronic kidney disease patients. In addition, several publications discussed the benefits of each treatment and possible risks associated with long term treatment. The current guidelines provide advice to health care professionals on how to screen chronic kidney disease patients for anaemia, which patients to investigate for other causes of anaemia, when and how to treat patients with different medications, how to ensure safe prescribing of treatment and how to diagnose and manage complications associated with anaemia and the drugs used for its treatment. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 11 | 69% |
| India | 2 | 13% |
| Spain | 1 | 6% |
| China | 1 | 6% |
| Unknown | 1 | 6% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 50% |
| Scientists | 6 | 38% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 462 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 462 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 59 | 13% |
| Student > Master | 58 | 13% |
| Other | 35 | 8% |
| Researcher | 30 | 6% |
| Student > Postgraduate | 30 | 6% |
| Other | 59 | 13% |
| Unknown | 191 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 143 | 31% |
| Nursing and Health Professions | 39 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 27 | 6% |
| Biochemistry, Genetics and Molecular Biology | 17 | 4% |
| Business, Management and Accounting | 9 | 2% |
| Other | 30 | 6% |
| Unknown | 197 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2017.
All research outputs
#2,360,614
of 23,009,818 outputs
Outputs from BMC Nephrology
#198
of 2,497 outputs
Outputs of similar age
#55,158
of 437,899 outputs
Outputs of similar age from BMC Nephrology
#4
of 43 outputs
Altmetric has tracked 23,009,818 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,497 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,899 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.